Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Chronic Insomnia – Market Insights, Epidemiology, and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the Chronic Insomnia, his…
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, March 11, 2021 to report financial results for the year ended December 31, 2020 and discuss recent business hig…
Christophe Bourdon’s Deep Commercialization Background and Vast International Experience Make Him the Ideal CEO For Orphazyme
CEO Relocation to Copenhagen Seen as a Positive Sign of the Commercial Potential of Arimoclomol
LOS ANGELES–(BUSINESS WIRE)…
Ms. Harild Brings Over 30 Years of Medical Device and Pharmaceutical Industry Experience
COPENHAGEN, Denmark–(BUSINESS WIRE)–Neurescue, a clinical-stage medical device company bringing to market the world’s first computer-aided balloon catheter for …
DUBLIN–(BUSINESS WIRE)–The “Global Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development, Academic Research), End-user (Biotechnology Companies, CROs…
CLEMSON, S.C. & BERLIN–(BUSINESS WIRE)–Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again. It is the latest addition to the growing portfolio of Kizoo Tech…
DUBLIN–(BUSINESS WIRE)–The “Wearable Injectors Market Size, Share & Trends Analysis Report by Type (On-body, Off-body), by Technology (Spring-based, Motor-driven), by Application (Oncology, Autoimmune Diseases), by End Use, and Segment Forecasts,…
– Phase 2 Initiation Triggers $25 Million Milestone to Dicerna –
LEXINGTON, Mass.–(BUSINESS WIRE)–Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) …
Initiated Phase 3 Trial of SY-1425 in Combination with Azacitidine in RARA-Positive Newly Diagnosed Higher-Risk MDS Patients
On Track to Initiate Two Additional Clinical Trials Across Hematology Franchise in 2H 2021
On Track to Report Additional Dos…
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief …